Health Canada receives applications concerning clinical trials on a regular basis.  This time, the licensed producer of natural EU-GMP psilocybin and MDMA Optimi Health Corp. (OTCQX: OPTHF) together with ATMA Journey Centers say they intend to submit a Phase I clinical trial application (CTA) to document the safety of Optimi’s natural psilocybin biomass and MDMA in healthy patients.

The study plans to assess both safety -blood pressure, temperature, heart rate, ECG readings- and additional markers -i.e. a mystical experience questionnaire- …

Full story available on Benzinga.com